We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





MEDICA 2021 + COMPAMED 2021 Far Exceed Expectations and Achieve Extremely Successful Results

By LabMedica International staff writers
Posted on 19 Nov 2021

After their four-day run as an in-person event, MEDICA and COMPAMED achieved extremely successful results in Düsseldorf, Germany. More...

From 15 to 18 November 2021, the world’s leading information and communication platforms for the medical technology industry and its supplier sector presented a wealth of convincing innovations as well as accompanying programs that covered a wide range of topics (supplemented by digital offers) and did justice to their internationally prestigious position. 46,000 visitors (with an international share of 73%) from 150 countries seized the opportunity to engage in person with the 3,033 MEDICA and 490 COMPAMED exhibitors in Düsseldorf, obtaining information on the comprehensive range of innovations for outpatient and inpatient care, including every step of their development and manufacture, and trying out many innovative products live in the trade fair halls.

The industry portals MEDICA.de and COMPAMED.de added a range of offers in line with the live events at the trade fairs. This allowed users to access livestreams to watch the stage programs of all expert forums that had been integrated into the trade fairs as well as the 44th German Hospital Conference and the MEDICA MEDICINE + SPORTS CONFERENCE; network via the special Matchmaking tool; and obtain information on innovative products in the exhibitors’ online showrooms.

As expected, COVID-19 and the findings gained to date while managing the pandemic with regard to the implementation of new therapeutic approaches and care concepts were recurring themes in many talks at the forums and accompanying conferences. The MEDICA MEDICINE + SPORTS CONFERENCE, for example, took a closer look at how to get back into sports after suffering from long COVID, while the MEDICA ECON FORUM and the MEDICA HEALTH IT FORUM focused on digitizing processes in the healthcare system.

In line with these themes, exhibitors offered many innovations for the clinical and outpatient field. And the young start-up scene was heavily involved as well, something that was impressively proven during the thrilling pitch competitions held as part of the 10th MEDICA Startup COMPETITION and the 13th Healthcare Innovation World Cup, which took place on the MEDICA CONNECTED HEALTHCARE FORUM program stage. The 13th Healthcare Innovation World Cup focused on innovative devices and smart applications for digital networking and process integration, with an eye to the Internet of Medical Things. From among 300 entries, the jury selected 12 start-ups for the finals on 15 November. Ideas ranged from artificial intelligence (AI) and health apps to robotics at the 10th MEDICA Startup COMPETITION (on 16 November).

Trends along the entire process chain of medical technological manufacture and product developments dominated both the trade fair business of exhibitors and visitors at COMPAMED (which took place in Halls 13 and 14 this time around) and the stage programs of the two integrated expert forums. Innovative substances played just as great a role as innovative, printed electronics, smart sensor solutions and microfluidic options to resolve challenges in point of care diagnostics.

“The atmosphere in the trade fair halls was relaxed and characterised by a sense of optimism throughout; conversations with our customers have shown that in many cases, we have exceeded expectations. People were finally able to establish new and intensify existing contacts in person,” said Erhard Wienkamp, Managing Director of Messe Düsseldorf.

“The numbers are encouraging, and were hardly expected to be at this level in spring. With the combination of trade fair events and digital supplements, MEDICA and COMPAMED have given the industry strong stimuli. The exhibitors are happy to have come to Düsseldorf and are already actively inquiring about options to take part next year,” added Christian Grosser, Director Health & Medical Technologies at Messe Düsseldorf, thus reflecting the positive signals fed back by participants and trade associations alike.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.